评估 Triphala 对高脂饮食喂养大鼠的抗高血脂作用:两种组合的研究。

Ayu Pub Date : 2022-07-01 Epub Date: 2023-10-09 DOI:10.4103/ayu.AYU_74_19
Suman Rana, Princy Louis Palatty, Ruby Benson, Benson Mathai Kochikuzhyil, Manjeshwar Shrinath Baliga
{"title":"评估 Triphala 对高脂饮食喂养大鼠的抗高血脂作用:两种组合的研究。","authors":"Suman Rana, Princy Louis Palatty, Ruby Benson, Benson Mathai Kochikuzhyil, Manjeshwar Shrinath Baliga","doi":"10.4103/ayu.AYU_74_19","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hyperlipidemia is one of the major risk factors for coronary heart disease and stroke. <i>Triphala</i>, a polyherbal Ayurvedic formulation made from dried fruits of <i>Haritaki</i> (<i>Terminalia chebula</i> Retz.), <i>Bibhitaki</i> (<i>Terminalia bellirica</i> Roxb.), and <i>Amalaki</i> (<i>Phyllanthus emblica</i> Gaertn.) has been suggested to be useful in mitigating hyperlipidemia. In the Ayurveda texts, depending on the patient's condition and body type, <i>Triphala</i> is formulated and used in one of the two combination (1:1:1 and 1:2:4 of individual constituents) forms.</p><p><strong>Aims: </strong>The present study aimed at evaluating the efficacy of two combinations (1:1:1 and 1:2:4 of individual constituents) of <i>Triphala</i> against high fat diet induced-hyperlipidemia in rats.</p><p><strong>Materials and method: </strong>Hyperlipidemia was induced in Spraque-Dawley albino rats by feeding them with high fat diet. The animals were concomitantly administered with graded dose of one of the two combination (combination of <i>Haritaki</i>, <i>Bibhitaki</i>, and <i>Amalaki</i> in ratio of 1:1:1 or 1:2:4, respectively) of <i>Triphala</i> (250, 500, or 1000 mg/kg body wt.) or atorvastatin. The animals were sacrificed on day 22 and serum was processed for lipid profile and the liver for lipid peroxidation. The statistical analysis was performed by the mean analysis of variance followed by Dunnet's test.</p><p><strong>Results: </strong>The results indicated that when compared to placebo group, levels of serum total cholesterol, and triglyceride were significantly lower, while high-density lipoprotein cholesterol increased in both the <i>Triphala</i> combination and atorvastatin groups. Of the two groups of <i>Triphala</i>, the formulation having 1:2:4 ratio was better than the 1:1:1. The group having highest drug dose (1000 mg/kg body wt.) of 1:2:4 formulation was better than atorvastatin in rectifying high fat diet-induced dyslipidemia and the atherogenic index was equal to that of atorvastatin.</p><p><strong>Conclusions: </strong>The results of the study indicate that of the two <i>Triphala</i> formulations, the 1:2:4 ratio was better than the 1:1:1 ratio for anti-hyper-lipidemic effects.</p>","PeriodicalId":502094,"journal":{"name":"Ayu","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10710234/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluation of the anti-hyperlipidemic effects of <i>Triphala</i> in high fat diet fed rats: Studies with two combinations.\",\"authors\":\"Suman Rana, Princy Louis Palatty, Ruby Benson, Benson Mathai Kochikuzhyil, Manjeshwar Shrinath Baliga\",\"doi\":\"10.4103/ayu.AYU_74_19\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Hyperlipidemia is one of the major risk factors for coronary heart disease and stroke. <i>Triphala</i>, a polyherbal Ayurvedic formulation made from dried fruits of <i>Haritaki</i> (<i>Terminalia chebula</i> Retz.), <i>Bibhitaki</i> (<i>Terminalia bellirica</i> Roxb.), and <i>Amalaki</i> (<i>Phyllanthus emblica</i> Gaertn.) has been suggested to be useful in mitigating hyperlipidemia. In the Ayurveda texts, depending on the patient's condition and body type, <i>Triphala</i> is formulated and used in one of the two combination (1:1:1 and 1:2:4 of individual constituents) forms.</p><p><strong>Aims: </strong>The present study aimed at evaluating the efficacy of two combinations (1:1:1 and 1:2:4 of individual constituents) of <i>Triphala</i> against high fat diet induced-hyperlipidemia in rats.</p><p><strong>Materials and method: </strong>Hyperlipidemia was induced in Spraque-Dawley albino rats by feeding them with high fat diet. The animals were concomitantly administered with graded dose of one of the two combination (combination of <i>Haritaki</i>, <i>Bibhitaki</i>, and <i>Amalaki</i> in ratio of 1:1:1 or 1:2:4, respectively) of <i>Triphala</i> (250, 500, or 1000 mg/kg body wt.) or atorvastatin. The animals were sacrificed on day 22 and serum was processed for lipid profile and the liver for lipid peroxidation. The statistical analysis was performed by the mean analysis of variance followed by Dunnet's test.</p><p><strong>Results: </strong>The results indicated that when compared to placebo group, levels of serum total cholesterol, and triglyceride were significantly lower, while high-density lipoprotein cholesterol increased in both the <i>Triphala</i> combination and atorvastatin groups. Of the two groups of <i>Triphala</i>, the formulation having 1:2:4 ratio was better than the 1:1:1. The group having highest drug dose (1000 mg/kg body wt.) of 1:2:4 formulation was better than atorvastatin in rectifying high fat diet-induced dyslipidemia and the atherogenic index was equal to that of atorvastatin.</p><p><strong>Conclusions: </strong>The results of the study indicate that of the two <i>Triphala</i> formulations, the 1:2:4 ratio was better than the 1:1:1 ratio for anti-hyper-lipidemic effects.</p>\",\"PeriodicalId\":502094,\"journal\":{\"name\":\"Ayu\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10710234/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ayu\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ayu.AYU_74_19\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/10/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ayu","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ayu.AYU_74_19","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:高脂血症是冠心病和中风的主要危险因素之一:高脂血症是冠心病和中风的主要危险因素之一。Triphala是一种多草药阿育吠陀配方,由Haritaki(Terminalia chebula Retz.)、Bibhitaki(Terminalia bellirica Roxb.)和Amalaki(Phyllanthus emblica Gaertn.)的干燥果实制成,被认为有助于缓解高脂血症。在阿育吠陀经文中,根据患者的病情和体质,Triphala 以两种组合形式(1:1:1 和 1:2:4 的单个成分)之一配制和使用:用高脂肪饮食诱导 Spraque-Dawley 白化大鼠患高脂血症。同时给动物服用不同剂量的 Triphala(250、500 或 1000 毫克/千克体重)或阿托伐他汀组合(Haritaki、Bibhitaki 和 Amalaki 的组合,比例分别为 1:1:1 或 1:2:4)中的一种。动物在第 22 天被处死,并对血清进行脂质分析,对肝脏进行脂质过氧化分析。统计分析采用均值方差分析,然后进行 Dunnet 检验:结果表明,与安慰剂组相比,三苯氧胺联合用药组和阿托伐他汀组的血清总胆固醇和甘油三酯水平明显降低,而高密度脂蛋白胆固醇水平则有所上升。在两组三苯氧胺中,1:2:4 比例的配方优于 1:1:1。药物剂量最高(1000 毫克/千克体重)的 1:2:4 配方组在纠正高脂饮食引起的血脂异常方面优于阿托伐他汀,其动脉粥样硬化指数与阿托伐他汀相同:研究结果表明,在两种Triphala配方中,1:2:4比例的抗高血脂效果优于1:1:1比例的配方。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Evaluation of the anti-hyperlipidemic effects of Triphala in high fat diet fed rats: Studies with two combinations.

Background: Hyperlipidemia is one of the major risk factors for coronary heart disease and stroke. Triphala, a polyherbal Ayurvedic formulation made from dried fruits of Haritaki (Terminalia chebula Retz.), Bibhitaki (Terminalia bellirica Roxb.), and Amalaki (Phyllanthus emblica Gaertn.) has been suggested to be useful in mitigating hyperlipidemia. In the Ayurveda texts, depending on the patient's condition and body type, Triphala is formulated and used in one of the two combination (1:1:1 and 1:2:4 of individual constituents) forms.

Aims: The present study aimed at evaluating the efficacy of two combinations (1:1:1 and 1:2:4 of individual constituents) of Triphala against high fat diet induced-hyperlipidemia in rats.

Materials and method: Hyperlipidemia was induced in Spraque-Dawley albino rats by feeding them with high fat diet. The animals were concomitantly administered with graded dose of one of the two combination (combination of Haritaki, Bibhitaki, and Amalaki in ratio of 1:1:1 or 1:2:4, respectively) of Triphala (250, 500, or 1000 mg/kg body wt.) or atorvastatin. The animals were sacrificed on day 22 and serum was processed for lipid profile and the liver for lipid peroxidation. The statistical analysis was performed by the mean analysis of variance followed by Dunnet's test.

Results: The results indicated that when compared to placebo group, levels of serum total cholesterol, and triglyceride were significantly lower, while high-density lipoprotein cholesterol increased in both the Triphala combination and atorvastatin groups. Of the two groups of Triphala, the formulation having 1:2:4 ratio was better than the 1:1:1. The group having highest drug dose (1000 mg/kg body wt.) of 1:2:4 formulation was better than atorvastatin in rectifying high fat diet-induced dyslipidemia and the atherogenic index was equal to that of atorvastatin.

Conclusions: The results of the study indicate that of the two Triphala formulations, the 1:2:4 ratio was better than the 1:1:1 ratio for anti-hyper-lipidemic effects.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Ayu
Ayu
自引率
0.00%
发文量
0
期刊最新文献
Safety and efficacy of COROPROTECT kit as an add-on therapy in the management of mild-to-moderate COVID-19: A randomized, placebo-controlled trial. Use of checkerboard assay to determine the synergy between essential oils extracted from leaves of Aegle marmelos (L.) Correa and nystatin against Candida albicans. Comparative Pharmacognostic study of market samples of Tagara collected from five different markets of Kerala with the official source plant Valeriana jatamansi Jones ex Roxb. Erratum: Balchaturbhadra Churna as a potential medicine for SARS-CoV2 infection in pediatric setting an in silico study. Evaluation of the anti-arthritic activity of Rhuflex-F - A proprietary Ayurvedic herbomineral formulation in albino rats.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1